Clinical trial · Observational
ObServatory Children Acute RElated Therapy Leukemia
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Acute Myeloid Leukemias (AML) of the child are a rare disease and its prognosis varies according to the subgroup. Secondary AMLs remain a subgroup of poor prognosis, whose cytogenetic and molecular characteristics and prognostic value differ in part from de novo AMLs. The purpose of this national observatory is to record scientific and medical information on cases of secondary AML that have occurred in France since 2013 in order to improve the treatment of children and adolescents with this disease in the years to come. This national observatory will contribute to better knowledge and progress in research into these diseases.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia, Myeloid, Acute | Leukemia | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| collection of the clinical and biological characteristics of secondary AMLs in children | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Secondary Acute Myeloid Leukemias (AML) of the child
- interventionNames
- Other: collection of the clinical and biological characteristics of secondary AMLs in children
Primary outcomes (17)
- measure
- potential clinical-biological prognostic factors - patient characterics
- timeFrame
- through study completion, an average of 6 months
- description
- patient characteristics are sex, patient's age at the start of treatment for secondary AML, date of birth, personal history of genetic predisposition (including brittle diseases - see below), family history of cancers (1st or 2nd degree)
- measure
- potential clinical-biological prognostic factors - first cancer characteristics
- timeFrame
- through study completion, an average of 6 months after patient inclusion
- description
- First cancer characteristics are age of onset, determined from the date of diagnosis, and histology, determined by anatomo-pathological diagnosis.
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients aged 0-18 years * Patient with first cancer * Diagnosis of secondary AML * Patients treated in a SFCE (Société française des cancers de l'enfant) center * For cases included in the prospective from March 2019 onwards: Consent of holders of parental authority and consent of the child of understanding age Exclusion Criteria: None
References
Publications (0)
Data not yet available